Print the grid, tape it inside a kitchen cupboard, look at it for a minute a day with each eye separately. Cost is zero, the habit takes longer to remember than to do. The catch — it only earns daily use for a specific group: anyone an eye doctor has already told has early macular changes, anyone watching the second eye after the first one was treated for wet AMD, anyone with a parent or sibling with the condition past about age 60. For everyone else, the test will tell you nothing useful and occasionally tell you something alarming that isn't real.
Healthy eyes see straight lines as straight. The bleeding form of macular degeneration — usually called wet AMD — pushes a small dome of fluid under the central retina, lifting a patch of photoreceptors into a curve. The brain still reads those photoreceptors as a flat surface, so a grid line that crosses the dome gets perceived as bent. That's the wavy segment people see on the test Tripathy & Salini 2023. The same logic catches a wrinkly layer of scar tissue on the retinal surface (an epiretinal membrane), or missing patches from the late stages of the dry form of AMD — those show up as blank, gray, or dark squares rather than wavy lines.
The grid samples a 20-degree window in the very center of vision — roughly the size of the page when held at reading distance. Whatever lives outside that window the test cannot see, full stop. Peripheral retinal problems, glaucoma, cataract — none of them produce a positive Amsler grid until they reach the center.
How well it actually works
The numbers tell two stories. Against a healthy eye with no macular problem at all, the grid is almost perfectly specific — basically nobody clean fails it. Against an eye that already has dry AMD watching for the wet conversion (which is the actual use case), the picture is duller: about seven in ten wet conversions get caught, and about a third of stable dry eyes give a false positive on any given day Bjerager et al. 2023. It is not a great test on paper. It is a defensible one in practice because it costs nothing, takes under a minute, and the alternative for most patients between clinic visits is no monitoring at all.
The American Academy of Ophthalmology still recommends home Amsler testing in its practice pattern for AMD patients with at-risk macular changes, alongside (not instead of) scheduled dilated exams AAO PPP 2019. The endorsement comes with the caveat that a clean grid does not mean a clean retina — patients who use the grid daily, see nothing, and skip the clinic visit get caught later than patients who do the opposite.
Who actually benefits
The grid earns its daily slot for a specific list and is mostly noise for everyone else. Three groups, in descending order of how well-evidenced the use is:
- One wet eye, watching the other. The canonical use case — most accuracy studies and the HOME trial were anchored on this group. Once one eye converts, the fellow-eye annual conversion risk runs near 10% per year, and same-week detection is the largest single lever on long-term acuity in the second eye Chew et al. 2014.
- Diagnosed intermediate dry AMD. An ophthalmologist has already seen large drusen — yellow deposits visible on a dilated exam — putting annual conversion to the wet form at roughly 3 to 4 percent and five-year conversion near 18% AREDS 2001. This is the group most ophthalmologists send home with a printed grid.
- First-degree family history plus stacking risk. A parent or sibling with AMD doubles or triples baseline risk; combined with smoking, European ancestry, and age past 60, daily grid use becomes defensible even without a confirmed diagnosis.
Outside those three — healthy adults under 50, no family history, no diagnosed dry AMD — daily Amsler use generates more false alarms than real catches. The test is a monitoring tool for people who already know they're in the at-risk pool, not a screen for the general population Bjerager et al. 2023. The way most people first find out they're in that pool is the baseline eye exam at 40 — the dilated check that picks up early macular changes before there's anything for the grid to watch.
How to do it
Three things are needed: the grid, your reading correction (the glasses or contacts you wear for a book), and a wall. Hold the grid at reading distance — about a foot from your face, the same distance you'd hold a paperback — in good ambient room light. Avoid testing right after looking at a bright phone or a window; the photostress will produce false positives Tripathy & Salini 2023. Cover one eye with your palm — not both, ever — and stare at the central dot. Don't move your gaze. While looking at the dot, notice in your peripheral vision whether all four corners of the grid are visible at once, whether any lines look wavy, broken, or doubled, and whether any squares look gray, dark, or completely blank. Switch hands, switch eyes, repeat. The whole sequence is under a minute.
How the test fails
Three structural failure modes are worth knowing before relying on this. First, the visual system fills in small blank spots when it can't see them — a quirk called perceptual completion. A genuine blind patch under roughly 6 degrees across will get plastered over by the brain and look like normal grid Tripathy & Salini 2023. Second, testing with both eyes open is worthless: the unaffected eye fills in for the affected one, and the grid looks clean. Each eye gets its own minute with the other one covered, or the test does nothing. Third, the test only sees the central 20 degrees. Macular problems sitting outside that zone will not register until they progress inward.
The most common misconception is that the grid is a screen — a tool a healthy adult uses to check for AMD the way they'd check their blood pressure. It isn't. A 45-year-old with no family history who tries this for a month will get a few false positives from migraine aura, a stretch of dry eye, an episode of staring too long, or a tired evening — and learn, wrongly, either to ignore the test or to fear something they don't have. The grid earns daily use only where the underlying conversion risk is high enough that catching a true positive outweighs the steady drip of false ones.
The second misconception, more dangerous than the first, is that a clean grid means a clean retina. It doesn't. A patient with stable daily grids who skips the dilated exam because "the test was fine" gets diagnosed at the next visit with disease the grid never had the resolution to catch Bjerager et al. 2023. The grid is an early-warning bell between visits, not a substitute for the visits themselves AAO PPP 2019.
What you're trying to catch
Untreated wet AMD is not a slow blur. It is a small bent line that becomes a small gray smudge that becomes a permanent dark hole in the center of vision, over weeks to a few months. The face of the person across the table is the part that disappears — your own face in the mirror loses the eyes and nose, leaving the hairline. The number on a price tag, the word in the middle of a sentence, the road sign at distance — all gone from one eye, often before the brain stops compensating from the other. AMD is the leading cause of irreversible legal blindness in adults over 60 in developed countries; global prevalence runs near 8.7% in adults between 45 and 85 and climbs sharply with age, with roughly 196 million people affected worldwide as of 2020 and a projected 288 million by 2040 Wong et al. 2014.
Anti-VEGF injections — the standard treatment, given into the eye every few weeks at the start — cannot rebuild photoreceptors that died under leaking fluid. They can stop further damage and preserve the acuity that's left. The difference between catching the conversion in the week it happens and catching it three months later, at the next scheduled clinic visit, shows up on the eye chart for the rest of the patient's life: the long-term acuity in a wet-AMD eye is set largely by the visual acuity at the moment treatment begins CATT 2016. Years of independent reading, driving, and face recognition turn on a one-week window.
Better tools, where you can get them
The grid is the floor of home monitoring, not the ceiling. Three alternatives are worth knowing about.
ForeseeHome. A tabletop device that flashes dotted lines with small misalignments and asks the user to point at the bend. It exploits a quirk of human vision — hyperacuity — that's more sensitive to small distortions than line-perception is. In direct head-to-head against the paper grid in confirmed wet AMD eyes, the device caught 9 out of 10 cases; the grid caught about 5 of 10 Loewenstein 2003. Medicare covers it in the US for the high-risk dry AMD population. The device is the demonstrated upgrade for anyone the cost or insurance covers.
Smartphone hyperacuity apps. A handful of FDA-cleared apps (MyVisionTrack, AlleyeApp) use similar hyperacuity tests on a phone screen. The validation cohorts are still small. Plausibly an intermediate step for patients who don't qualify for ForeseeHome but want something better than the paper grid.
Shorter intervals between clinic visits with OCT. The unglamorous upgrade. An optical coherence tomography scanner — the standard imaging tool in any retina clinic — sees subretinal fluid days to weeks before the patient sees a wavy line. The single most effective monitoring upgrade for high-risk patients is a 6-monthly dilated exam with OCT instead of an annual one, with home Amsler in between. The grid is not competing with OCT; the grid is what tells the patient when to ask for an OCT outside the schedule AAO PPP 2019.
Adjacent topics worth following up on: the AREDS2 supplement formula, which slows progression from intermediate dry AMD to the advanced form by roughly a quarter over five years AREDS 2001; smoking cessation, the single largest modifiable AMD risk factor; the dilated eye exam itself, which is the only setting in which AMD gets diagnosed in the first place; and the OCT scan — the technology behind every modern wet AMD diagnosis and treatment decision.
- — The grid catches macular changes at home; the dilated exam at 40 is the baseline it builds on.
- — Diabetes can swell the macula too, bending the same grid lines. If you're diabetic, the yearly dilated exam is the real backstop.
- — While the grid watches for AMD, lutein and zeaxanthin are the diet and supplement lever that slows it.
- — Bent lines on the grid flag the macula; new flashes and a creeping curtain flag a retinal tear — know which symptom maps to which.
- — A sudden full blackout in one eye isn't what this grid catches — that's a stroke emergency, not a macular check.
- — Protecting your eyes from UV is part of guarding the macula the grid keeps watch on.
- — Glaucoma is the other silent vision-stealer, but it hides where this grid won't show, so book the comprehensive exam.
Substance and claimed effects
The Amsler grid is a printed (or digital) square of black horizontal and vertical lines on a white background, 10 cm by 10 cm, with a central fixation dot — a self-administered test for distortion (metamorphopsia) or blind spots (scotoma) in the central 20° of each eye's visual field, introduced by Swiss ophthalmologist Marc Amsler in 1947 Tripathy & Salini 2023. The claimed effects are entirely informational: the test does not treat anything; it generates a signal that triggers an unscheduled ophthalmology visit when the user perceives new distortion, blank spots, or wavy lines on the grid that were not there at the prior check. The downstream pathway that gives the test its value is anti-VEGF therapy for newly converted neovascular age-related macular degeneration (nAMD), where earlier detection — and therefore smaller baseline lesion size and better baseline visual acuity — predicts substantially better long-term acuity outcomes Chew et al. 2014 CATT 2016. This entry covers the grid's diagnostic accuracy, the appropriate at-risk population, the testing protocol and cadence, the false-positive considerations and competing causes of metamorphopsia, the referral threshold, and the alternatives that have largely superseded Amsler in the populations who can access them.
Evidence by addressing question
mechanism
Science / mechanism. A healthy macula projects parallel grid lines as parallel; the retinotopic map is locally linear. Two distinct macular pathologies disrupt this. (1) Subretinal fluid or blood from a choroidal neovascular membrane (wet AMD, central serous chorioretinopathy) physically elevates the photoreceptor layer in a domed shape; the brain still reads its retinal coordinates as planar, so a row of photoreceptors that physically forms a hill is perceived as a curved line — the classic "wavy" or "bent" segment Tripathy & Salini 2023. (2) An epiretinal membrane contracts the inner retinal surface, distorting photoreceptor spacing and producing similar metamorphopsia with a typically more diffuse, irregular pattern Tripathy & Salini 2023. Geographic atrophy and dense drusen produce true scotomas — missing or grayed-out grid squares rather than distortion. The Amsler grid samples a 20° central field at the conventional 33 cm test distance; lesions outside this zone are invisible to the test.
Limitations of the perceptual mechanism. Two effects degrade test sensitivity even when the lesion is in the sampled field. First, the absence of fixation monitoring: small scotomas can be invisible because the visual system performs perceptual completion, inferring a continuous grid where one is not actually being sensed Tripathy & Salini 2023. Second, the spatial resolution floor: scotomas under approximately 6° in diameter are not reliably detected at the standard test distance Tripathy & Salini 2023.
evidence
Diagnostic accuracy — meta-analytic estimate. The most rigorous synthesis is Bjerager et al. 2023, a JAMA Ophthalmology meta-analysis of 10 studies covering 1,890 eyes, all of which used supervised in-clinic testing rather than the at-home setting in which the grid is actually deployed Bjerager et al. 2023. Pooled performance: against healthy controls, sensitivity for neovascular AMD was 67% (95% CI 51–79%) with specificity 99%; against eyes with non-neovascular ("dry") AMD — the clinically relevant comparison, since the population of grid users is precisely those with known dry AMD watching for conversion — sensitivity was 71% (60–80%) but specificity dropped to 63% Bjerager et al. 2023. The dry-AMD comparison is the one that matters for the home-monitoring use case, and a specificity in the low 60s means roughly one in three eyes with stable dry AMD will give a positive grid on any given check. The American Academy of Ophthalmology's editorial commentary on the meta-analysis concluded the Amsler grid "may also provide a false sense of security" and that "patients should be encouraged to have regular ophthalmic exams, regardless of their self-assessment results."
The HOME RCT — Amsler as the control arm. The AREDS2-HOME study randomized 1,520 participants (mean age 72.5 years) with bilateral large drusen or unilateral nAMD to standard care including monthly Amsler grid plus monthly symptom-prompting questionnaire versus the ForeseeHome preferential hyperacuity perimeter Chew et al. 2014. The trial stopped early for efficacy. At CNV detection, the device arm had lost a median of 4 ETDRS letters from baseline versus 9 in the standard-care arm (P = 0.021), with 87% of device-arm conversions still at visual acuity 20/40 or better versus 62% in the standard-care arm Chew et al. 2014. The grid was the control arm — the trial does not prove the grid is better than nothing, only that PHP beats grid-plus-questionnaire. By implication, the comparator beat by PHP is the best available reading of grid-based monitoring in a motivated, supervised cohort.
Earlier head-to-head — PHP vs grid. Loewenstein 2003 compared the original paper Amsler with an earlier PHP prototype on 19 eyes with confirmed neovascular AMD: 19/19 (100%) positive on PHP, 10/19 (53%) positive on Amsler Loewenstein 2003. Smaller study, but anchors the magnitude of the sensitivity gap.
practice / clinical consensus
The AAO's 2019 Preferred Practice Pattern (carried forward in subsequent updates) recommends that "patients with early AMD and/or a family history of AMD should be encouraged to assess their own visual function using monocular vision testing (i.e., Amsler grid or electronic home monitoring) and have scheduled dilated eye examinations" AAO PPP 2019. The grid remains the default home-monitoring tool by virtue of being free, requiring no device, and being printable; the practice pattern explicitly acknowledges its accuracy ceiling and frames home monitoring as supplementary, not substitutive of dilated exams. Most retina specialists recommend daily testing for patients with diagnosed intermediate dry AMD or one wet eye watching the fellow eye; the StatPearls reference cites a floor of "at least once weekly" Tripathy & Salini 2023. There is no evidence-based recommendation for routine Amsler grid use in adults without AMD or family history — and given the ~63% specificity against dry AMD, a screening application in healthy adults would be heavily false-positive-dominated.
protocol
Standardized procedure per StatPearls and AAO patient education: held at 33 cm (about 14 inches) from the eye, wearing reading correction, in good ambient light, avoiding bright light exposure immediately before testing (photostress can produce transient false positives), each eye tested separately with the other covered, fixating on the central dot and noting in peripheral vision whether all four corners of the grid are visible, whether any lines appear wavy, broken, blurred, or distorted, and whether any squares appear dark, gray, blank, or missing Tripathy & Salini 2023. Test duration is under one minute per eye. Recommended cadence depends on baseline risk: daily for intermediate dry AMD or fellow-eye monitoring after CNV in the other eye; less established for everyone else. The brief's "monthly" framing aligns with the HOME study control-arm protocol but is below the daily cadence most retina clinics recommend in high-risk patients.
contraindications and false positives
No medical contraindications — the test is non-invasive and risk-free. Sources of false positives: pre-existing fixed metamorphopsia from prior treated CNV, epiretinal membrane, central serous chorioretinopathy, vitreomacular traction, or any other macular pathology causes the grid to be positive every test; the user must learn their own "baseline" pattern and watch for change Tripathy & Salini 2023. Migraine aura, transient photostress, uncorrected near refractive error, dry eye with intermittent corneal distortion, and the perceptual-completion / fading effects can all produce one-off positive grids in eyes without retinal pathology. The 63% specificity against dry AMD in Bjerager 2023 reflects exactly this signal-to-noise problem Bjerager et al. 2023. Sources of false negatives are equally important and arguably more dangerous: scotomas under ~6° are missed, lesions outside the central 20° are invisible, fixation drift lets perceptual completion fill in real defects, and patients who test only once a day may convert and treat the new distortion as normal by the second day Tripathy & Salini 2023.
audience
The grid earns daily use in three groups, by descending evidence strength: (1) patients with neovascular AMD in one eye watching the fellow eye for conversion (this is the canonical use case and the population in HOME and most accuracy studies); (2) patients with intermediate or large-drusen dry AMD (AREDS category 3+) on AREDS2 supplementation, where the annualized conversion rate to advanced AMD is around 3–4% per year and roughly 18% over five years AREDS 2001; (3) patients with a first-degree family history of AMD plus other risk factors (smoking, European ancestry, age 60+). Outside these groups — healthy adults under 50, no family history, no diagnosed dry AMD — daily grid testing has no demonstrated benefit and would generate predominantly false positives.
failure-modes
The grid's failure mode is not random noise around an accurate signal — it is structured underdetection of small lesions and structured false positives in eyes with stable disease. The clinical consequence pattern reported by retina specialists: patients who use the grid daily and notice no change get false reassurance and skip or delay dilated exams, presenting at the next scheduled visit with already-established CNV and worse acuity than the cohort who came in because of a positive grid. The HOME study's mechanism of benefit is not that PHP catches every CNV — it is that PHP catches it earlier than self-reported symptoms in motivated patients who were also doing Amsler grids Chew et al. 2014. A second failure mode is binocular testing: patients who test both eyes simultaneously miss unilateral defects because the unaffected eye fills in the affected eye's scotoma. The grid only works monocularly.
alternatives
The PHP-based ForeseeHome device (FDA-cleared, Medicare-covered for AREDS category 3 / 4 monitoring) is the head-to-head superior tool — 90% sensitivity for CNV vs ~70% for grid in head-to-heads Loewenstein 2003, and a demonstrated 5-letter median acuity preservation in the RCT comparator Chew et al. 2014. Smartphone-based hyperacuity tests (e.g., MyVisionTrack, AlleyeApp) have FDA clearance and are an emerging middle path; the literature is thinner. The other competing intervention is shorter clinic-visit intervals with OCT — the technology that actually diagnoses CNV regardless of patient-reported symptoms. Annual dilated exams plus OCT for known dry AMD are the floor recommendation in PPP AAO PPP 2019.
stakes and payoff
The stakes are quantitatively well-characterized. CNV that converts dry AMD to wet AMD destroys central acuity over weeks to months when untreated; CATT 2-year data show baseline visual acuity at treatment initiation predicts 5-year acuity, with eyes treated at better baseline acuity retaining better final acuity CATT 2016. Wet AMD is the leading cause of irreversible legal blindness in adults over 60 in developed countries; global AMD prevalence is approximately 8.7% in adults 45–85 and rising sharply with age, with 196 million affected worldwide as of 2020 projected to 288 million by 2040 Wong et al. 2014. Anti-VEGF therapy (ranibizumab, aflibercept, bevacizumab, faricimab) cannot reverse photoreceptor loss but can prevent further leakage and preserve current acuity in the majority of treated eyes; the payoff of an Amsler-grid-triggered same-week ophthalmology visit is the difference between converting with 20/30 vision (treatable, often preservable) and converting with 20/200 (treatable, but permanent letter loss) Chew et al. 2014. Onset latency is reverse-loaded: the test has no value on Day 1 and may have no value for years; the year the user catches a converting macula, it may preserve a decade of independent reading, driving, and face recognition.
Credibility range
Optimist case. The Amsler grid is the cheapest, most accessible, most widely understood self-monitoring tool in ophthalmology. It is endorsed by every major guideline body for at-risk patients AAO PPP 2019. In motivated patients with high baseline vigilance, it does what it claims: detects new metamorphopsia with high specificity against healthy controls (99% in Bjerager 2023) and prompts emergency-tier evaluation for sudden new distortion, which in the relevant population is wet AMD until proven otherwise Bjerager et al. 2023. The downstream pathway — same-week OCT and anti-VEGF initiation at smaller lesion size — is the largest single determinant of long-term acuity preservation in wet AMD CATT 2016. The grid's failure modes are real but the alternative — relying on patient symptom report at the next scheduled clinic visit — is demonstrably worse, since the HOME standard-care arm was Amsler-plus-symptom-questionnaire and the device arm beat it by 5 letters Chew et al. 2014; the implicit floor is that the grid is doing some work above pure symptom-driven presentation.
Skeptic case. The Bjerager meta-analysis is damning when read literally: 71% sensitivity and 63% specificity against the dry-AMD comparison is below the threshold most clinicians would accept for a useful self-screen Bjerager et al. 2023. All meta-analyzed studies were supervised in-clinic — at-home unsupervised performance is almost certainly worse, given fixation drift, perceptual completion, and the absence of standardized lighting. The HOME trial does not prove the grid works in absolute terms; it proves PHP beats grid Chew et al. 2014. The grid was developed in 1947 in an era with no anti-VEGF therapy — its persistence is path dependence, not optimization. The 63% specificity against dry AMD implies a large false-positive load that translates to anxiety, unnecessary clinic visits, and habituation: patients with chronic false-positive checks learn to discount the grid, which is the opposite of what the protocol requires. The most defensible position is that the Amsler grid is a poor home monitor that survives because it is free and because the alternatives (PHP devices, OCT, retina clinic capacity) cannot reach population scale.
Author's call. The grid earns its place in the catalogue as a conditional intervention: for diagnosed intermediate dry AMD or fellow-eye monitoring after first-eye CNV, daily Amsler is the floor — not the ceiling — of self-monitoring, used adjunctively to (not instead of) scheduled dilated exams with OCT. For everyone outside that population, the test is closer to neutral than helpful — the false-positive load dominates the rare true-positive yield. Evidence is moderate (one good meta-analysis, one definitive RCT in which the grid was the control arm, decades of clinical use) but not strong. Controversy is modest: the field broadly agrees the grid is suboptimal but useful where nothing better is available; the disagreement is over whether the grid earns its place or has been superseded by PHP and smartphone hyperacuity.
Stakeholder and incentive map
- Clinical retina community — endorses the grid as a low-cost baseline; no direct incentive either way. The professional incentive is patient outcomes and clinic capacity, both of which favor home monitoring that triages clinic visits.
- Notal Vision (ForeseeHome maker) — direct commercial incentive to position PHP as superior; their study (HOME) is independently strong but worth flagging the financial structure.
- Guideline bodies (AAO, NICE) — institutional incentive to recommend free, evidence-supported tools; the Amsler grid clears that bar by inertia even where head-to-head trials suggest a better alternative.
- Anti-VEGF manufacturers (Genentech, Regeneron) — indirect incentive in any tool that triggers earlier treatment initiation. Larger treated population, more injections per patient over the disease course.
- Optometry / primary eye care — distributes printable Amsler grids as a low-friction patient-education artifact; reinforces the grid's persistence.
Population variability
- Age. AMD prevalence rises steeply with age — early AMD ~8% in 45–85, late AMD ~0.4%, prevalence highest over 85 Wong et al. 2014. Below 50, the grid is overwhelmingly likely to generate false positives in any reader.
- Ancestry. Early AMD is more common in those of European ancestry (~11%) than East Asian (~7%) or African ancestry, where AMD is uncommon at any age Wong et al. 2014. Population-relevant for whom the test is meaningful.
- Family history. First-degree relatives of AMD patients have roughly 2–3× baseline risk; meaningful enough to extend daily use to this group at age 50+.
- Smoking. Largest modifiable risk factor (2–4× hazard); current smokers in their 60s with family history are the highest-yield Amsler-grid population.
- Pre-existing macular pathology. Epiretinal membrane, treated CNV, geographic atrophy — these patients have permanent baseline grid positivity and need to learn their stable pattern before the grid is useful for monitoring.
- Test-taking competence. Patients who cannot maintain steady central fixation (severe dry eye, advanced cataract obscuring central fixation, cognitive impairment) cannot use the grid reliably.
Knowledge gaps
- No randomized trial of Amsler-grid-versus-no-monitoring exists. The grid has never been compared to a true do-nothing control in a powered study — all RCTs use it as the control arm.
- Unsupervised at-home test-retest reliability is poorly characterized. Bjerager-pooled accuracy is from clinic supervision; at-home performance is presumed worse but not quantified Bjerager et al. 2023.
- The cadence question — daily vs weekly vs monthly — is not directly evidence-based. Daily is recommended by convention; the test's underlying detect-or-miss logic does not strongly favor any specific cadence above weekly. Faster cadences may matter more for adherence than for sensitivity.
- Smartphone-based home monitoring tools (MyVisionTrack, AlleyeApp) have small validation cohorts; whether they outperform the grid in unsupervised real-world use is the open question that will likely settle the grid's role in the next 5–10 years.
- Long-term acuity outcomes specifically attributable to Amsler-triggered presentations (vs symptom-driven) have not been isolated outside the HOME study's control arm Chew et al. 2014.
Cadence call. The brief framed this as a "monthly" test; the article and meta settled on daily. The HOME trial's control arm used monthly grids and lost double the letters of the device arm Chew et al. 2014; AAO patient education and most retina clinics recommend daily for diagnosed dry AMD; StatPearls cites "at least weekly" as the floor Tripathy & Salini 2023. Monthly is below the evidence-supported cadence for the population that actually benefits. The article explains the daily framing in protocol and the audience-gating in audience.
Audience narrowing. Restricted to ages 40-59 and 60+. Under 40 AMD is vanishingly rare and the test produces almost only false positives. The article spends a paragraph in misconceptions explicitly disclaiming Amsler as a general-population screen, which felt more important than usual given that printable grids circulate as "anyone can do this" health content.
Scoring difficulty — health_short_term: 1. The grid has zero direct biological effect. Its benefit is contingent on (a) being in the at-risk population, (b) catching a real conversion event during a finite-duration window, (c) acting on the positive finding in time. Most readers using the grid will see no benefit because they will not develop CNV. Score 1 reflects the modest, conditional functional benefit in the population the article actually targets, per the holistic-scoring rule in meta.md §5a step 7. Considered 0 (no effect on the median reader) and 2 (a real preserved-acuity outcome in the catch-event subgroup); settled on 1 as the honest mid-point.
Mood scored 0 despite the case for non-zero. Daily home monitoring in AMD patients carries both peace-of-mind and anxiety loads; the false-positive rate against dry AMD is ~37%, which generates real anxiety from non-events. Net effect on inner wellbeing is plausibly zero in both directions; scored 0 rather than guess.
Controversy 2, not 3. The field broadly agrees the grid is suboptimal but defensible. The disagreement is over whether ForeseeHome and smartphone hyperacuity have made it obsolete, not over whether the grid works at all. That's calibration-level disagreement, not a 3-tier paradigm fight.
Future-link candidates (in related). amd-screening, areds2-supplements, dilated-eye-exam — none exist yet. The out-of-scope closer flags these for readers; the related-id list will activate once those entries are written.
Separate-entry candidates. ForeseeHome / preferential hyperacuity perimetry as its own entry (it's an actual device with insurance coverage and a separate scoring profile from the Amsler grid). OCT scanning cadence for at-risk patients. AREDS2 supplementation. Smoking cessation tied specifically to AMD risk reduction.
Excluded and why. Cut: detailed differential diagnosis of metamorphopsia (CSCR vs ERM vs vitreomacular traction) — diagnosis is the ophthalmologist's job once the grid is positive, not the reader's. Cut: specific anti-VEGF protocols and treat-and-extend regimens — that's a wet-AMD-treatment entry, not this one. Cut: full historical detail on Marc Amsler — interesting context but not load-bearing for the action.
Hard call — recommending against the test for low-risk readers. The article actively discourages daily Amsler for under-50s without family history. This is contrary to some patient-education content that promotes the grid as universal. Defended on the meta-analysis specificity numbers and the standard signal-to-noise argument Bjerager et al. 2023.
Amsler Grid
Under a minute per eye, once a day. The hard part is remembering, not doing it.
Moderate. Endorsed by ophthalmology guidelines for at-risk patients, but only catches roughly two thirds of the wet macular degeneration it is meant to flag — newer hyperacuity devices outperform it.
A one-minute daily check that, in someone with the right type of macular degeneration, catches the bleed early enough to save the central vision you read and drive with.